The signaling pathways and targets of traditional Chinese medicine and natural medicine in triple-negative breast cancer

Yang, Zhipeng; Zhang, Qiuhua; Yu, Linghong; Zhu, Jiayan; Cao, Yi; Gao, Xiufei

doi:10.1016/j.jep.2020.113249

Cited by 117 publications

(95 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast carcinoma is one of the most common malignancy and predominant cause of cancer-related death in women around the world, with a one in seven lifetime risk ( 1 – 3 ). Breast cancer, for the majority of patients, is treated with upfront surgery followed by other adjuvant (post-operative) modalities including radiotherapy, chemotherapy, endocrine therapy, immunotherapy, and adjuvant therapy of traditional Chinese medicine ( 4 – 9 ). Estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive breast cancer accounts for approximately 70% of all breast cancers, and 85% of those in women over 70 years of age ( 10 – 12 ).…”

Section: Introductionmentioning

confidence: 99%

DNAJC12 as a Mediator Between ESR1 and ERBB4 in Breast Carcinoma Cells

Lin

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Mutation of the DNAJC12 gene is typically associated with non-progressive Parkinsonism, but is also detectable in breast carcinoma where its contribution and mechanisms are unexplored. In breast carcinoma, ESR1 was positively correlated with DNAJC12 and ERBB4, and DNAJC12 was positively correlated with ERBB4. We used the GEO2R tool to compare differential gene expression of MCF-7 cells, following ESR1 knockdown (GEO database, E-GEOD-27473 array), and found decreased expression of DNAJC12 and ERBB4 in ESR1-silenced MCF-7 cells. The number of identical genes having correlativity with ESR1, DNAJC12, or ERBB4 was 12,165 (66.41%). These results suggest that ESR1 can promote the expression of DNAJC12 and ERBB4, and DNAJC12 can enhance the expression of ERBB4 in MCF-7 cells, implying that there may be a regulatory network among these three genes.

show abstract

Section: Introductionmentioning

confidence: 99%

DNAJC12 as a Mediator Between ESR1 and ERBB4 in Breast Carcinoma Cells

Lin

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Traditional Chinese medicinal herbs and their active constituents have long been evaluated for the treatment of carcinomas, including TNBCs, due to their ability to target multiple oncogenic signaling pathways [ 34 ]. Yuanhuacine ( 1 ), one of the constituents of the medicinal plant Daphne genkwa , has been previously reported to have in vitro cytotoxic activity against over a dozen diverse human cancer cell lines at concentrations ranging from 1–27 µM [ 21 , 35 , 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

Yuanhuacine Is a Potent and Selective Inhibitor of the Basal-Like 2 Subtype of Triple Negative Breast Cancer with Immunogenic Potential

Fermaintt

Peramuna

Cai

et al. 2021

Cancers

View full text Add to dashboard Cite

The heterogeneity of triple negative breast cancer (TNBC) has led to efforts to further subtype this disease with the hope of identifying new molecular liabilities and drug targets. Furthermore, the finding that TNBC is the most inherently immunogenic type of breast cancer provides the potential for effective treatment with immune checkpoint inhibitors and immune adjuvants. Thus, we devised a dual screen to identify compounds from natural product extracts with TNBC subtype selectivity that also promote the expression of cytokines associated with antitumor immunity. These efforts led to the identification of yuanhuacine (1) as a potent and highly selective inhibitor of the basal-like 2 (BL2) subtype of TNBC that also promoted an antitumor associated cytokine signature in immune cells. The mechanism of action of yuanhuacine for both phenotypes depends on activation of protein kinase C (PKC), defining a novel target for the treatment of this clinical TNBC subtype. Yuanhuacine showed potent antitumor efficacy in animals bearing BL2 tumors further demonstrating that PKC could function as a potential pharmacological target for the treatment of the BL2 subtype of TNBC.

show abstract

“…We found that the Maytenus compound may inhibit HCC cell proliferation by downregulating the EGFR-PI3K-AKT signaling pathway, but its specific direct targets are unknown, requiring further studies. Studies have shown that many traditional Chinese medicines generate anticancer activities through multiple targets [33,34]. Therefore, there are other possible molecular mechanisms by which Maytenus compound inhibits HCC proliferation.…”

Section: Discussionmentioning

confidence: 99%